SG10202002181UA - Imidazolonyl quinolines and use thereof as atm kinase inhibitors - Google Patents

Imidazolonyl quinolines and use thereof as atm kinase inhibitors

Info

Publication number
SG10202002181UA
SG10202002181UA SG10202002181UA SG10202002181UA SG10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA SG 10202002181U A SG10202002181U A SG 10202002181UA
Authority
SG
Singapore
Prior art keywords
imidazolonyl
quinolines
kinase inhibitors
atm kinase
atm
Prior art date
Application number
SG10202002181UA
Other languages
English (en)
Inventor
Thomas Fuchss
Kai Schiemann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG10202002181UA publication Critical patent/SG10202002181UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10202002181UA 2015-04-02 2016-03-31 Imidazolonyl quinolines and use thereof as atm kinase inhibitors SG10202002181UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02

Publications (1)

Publication Number Publication Date
SG10202002181UA true SG10202002181UA (en) 2020-05-28

Family

ID=52814780

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202002181UA SG10202002181UA (en) 2015-04-02 2016-03-31 Imidazolonyl quinolines and use thereof as atm kinase inhibitors
SG11201708065QA SG11201708065QA (en) 2015-04-02 2016-03-31 Imidazolonyl quinolines and use thereof as atm kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201708065QA SG11201708065QA (en) 2015-04-02 2016-03-31 Imidazolonyl quinolines and use thereof as atm kinase inhibitors

Country Status (24)

Country Link
US (5) US10457677B2 (hr)
EP (3) EP3868761B1 (hr)
JP (2) JP6791873B2 (hr)
KR (2) KR20240044525A (hr)
CN (3) CN111689963A (hr)
AU (3) AU2016239270B2 (hr)
BR (1) BR122019005502B1 (hr)
CA (1) CA2981365A1 (hr)
DK (2) DK3277681T3 (hr)
ES (3) ES2946507T3 (hr)
HR (2) HRP20191396T1 (hr)
HU (2) HUE054745T2 (hr)
IL (3) IL254714B (hr)
LT (2) LT3277681T (hr)
MX (2) MX2017012613A (hr)
PL (2) PL3560924T3 (hr)
PT (2) PT3560924T (hr)
RS (2) RS62082B1 (hr)
RU (1) RU2743343C2 (hr)
SG (2) SG10202002181UA (hr)
SI (2) SI3560924T1 (hr)
TR (1) TR201911244T4 (hr)
WO (1) WO2016155884A1 (hr)
ZA (1) ZA201707423B (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2946507T3 (es) * 2015-04-02 2023-07-20 Merck Patent Gmbh Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110312717B (zh) * 2017-02-27 2022-04-12 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
KR20200110377A (ko) 2018-01-12 2020-09-23 프로린크스 엘엘시 조합 용량의 독성을 최소화하기 위한 프로토콜 및 검증을 위한 조영제
EP3765019A1 (en) 2018-03-14 2021-01-20 Merck Patent GmbH Compounds and uses thereof to treat tumors in a subject
AU2019250361B2 (en) 2018-04-12 2023-03-23 Bayer Aktiengesellschaft Heteroaryl-triazole compounds as pesticides
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
GB201814487D0 (en) * 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
RU2771314C1 (ru) * 2018-09-30 2022-04-29 Медшайн Дискавери Инк. Производные хинолинпирролидин-2-она и их применение
SG11202110480YA (en) 2019-03-27 2021-10-28 Merck Patent Gmbh Imidazolonylquinoline compounds and therapeutic uses thereof
BR112022001067A2 (pt) * 2019-07-30 2022-05-24 Xrad Therapeutics Inc Inibidores duplos de atm e dna-pk para uso em terapia antitumoral
US20230044248A1 (en) 2019-11-01 2023-02-09 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
WO2021113506A1 (en) * 2019-12-04 2021-06-10 Chdi Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
US20230226041A1 (en) * 2020-06-18 2023-07-20 Merck Patent Gmbh Compounds for the treatment of viral infections
CN116194109A (zh) 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
BR112023002078A2 (pt) 2020-09-18 2023-03-28 Merck Patent Gmbh Preparação farmacêutica
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
CN101146810A (zh) * 2005-03-21 2008-03-19 菲尔若国际公司 制备1-取代的1H-咪唑并[4,5-c]喹啉-4-胺化合物的方法及其中间体
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2008103636A1 (en) 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
JP5519627B2 (ja) 2008-03-26 2014-06-11 ノバルティス アーゲー Ｖｅｇｆ促進性血管新生過程の強力なモジュレーターとしての５イミダゾキノリン誘導体およびピリミジン誘導体
WO2009152133A1 (en) 2008-06-10 2009-12-17 Abbott Laboratories Novel tricyclic compounds
US8778927B2 (en) 2008-10-01 2014-07-15 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CA2763821A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1h-imidazo[4,5-c]quinolinone derivatives
WO2010139747A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2011229542A1 (en) * 2010-03-16 2012-11-08 Merck Patent Gmbh Morpholinylquinazolines
AU2011273931B2 (en) * 2010-06-28 2015-04-23 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
JP2013544845A (ja) 2010-12-03 2013-12-19 ノバルティス アーゲー 医薬組成物
CN103012398B (zh) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
KR20150017367A (ko) 2012-06-06 2015-02-16 노파르티스 아게 종양 질환을 치료하기 위한 17-알파-히드록실라제 (c17,20-리아제) 억제제와 특이적 pi-3k 억제제의 조합물
NO2714752T3 (hr) 2014-05-08 2018-04-21
ES2946507T3 (es) * 2015-04-02 2023-07-20 Merck Patent Gmbh Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa

Also Published As

Publication number Publication date
US10975075B2 (en) 2021-04-13
EP3560924B1 (de) 2021-03-31
ZA201707423B (en) 2021-05-26
CA2981365A1 (en) 2016-10-06
WO2016155884A1 (de) 2016-10-06
DK3277681T3 (da) 2019-07-29
JP2021046403A (ja) 2021-03-25
US20230203034A1 (en) 2023-06-29
SI3560924T1 (sl) 2021-08-31
PL3277681T3 (pl) 2019-10-31
TR201911244T4 (tr) 2019-08-21
IL282584A (en) 2021-06-30
CN111689963A (zh) 2020-09-22
KR20240044525A (ko) 2024-04-04
AU2020204241B2 (en) 2022-11-17
BR112017020941A2 (pt) 2018-07-10
RU2017138100A3 (hr) 2019-10-04
AU2016239270B2 (en) 2020-03-26
IL271494B (en) 2021-05-31
KR20170132323A (ko) 2017-12-01
IL271494A (en) 2020-02-27
MX2017012613A (es) 2018-01-24
US10745399B2 (en) 2020-08-18
PL3560924T3 (pl) 2021-10-11
US20210198257A1 (en) 2021-07-01
EP3868761B1 (de) 2023-03-01
JP6791873B2 (ja) 2020-11-25
MX2020011558A (es) 2022-03-09
CN107889488B (zh) 2020-08-11
AU2022256215A1 (en) 2022-11-24
CN111747952A (zh) 2020-10-09
KR102652052B1 (ko) 2024-03-27
EP3277681A1 (de) 2018-02-07
EP3868761A1 (de) 2021-08-25
LT3560924T (lt) 2021-08-25
PT3277681T (pt) 2019-08-20
JP7111790B2 (ja) 2022-08-02
IL282584B (en) 2021-12-01
JP2018510191A (ja) 2018-04-12
ES2741853T3 (es) 2020-02-12
SI3277681T1 (sl) 2019-09-30
IL254714B (en) 2020-01-30
US10457677B2 (en) 2019-10-29
HRP20210981T1 (hr) 2021-09-17
EP3560924A1 (de) 2019-10-30
ES2946507T3 (es) 2023-07-20
RU2743343C2 (ru) 2021-02-17
US20190211013A1 (en) 2019-07-11
RU2017138100A (ru) 2019-05-08
US20180072715A1 (en) 2018-03-15
SG11201708065QA (en) 2017-10-30
RS62082B1 (sr) 2021-08-31
EP3277681B1 (de) 2019-05-08
PT3560924T (pt) 2021-07-02
AU2020204241A1 (en) 2020-07-16
DK3560924T3 (da) 2021-06-28
ES2880626T3 (es) 2021-11-25
HUE045477T2 (hu) 2019-12-30
AU2016239270A1 (en) 2017-11-16
BR122019005502B1 (pt) 2024-02-27
US11608338B2 (en) 2023-03-21
US20200325137A1 (en) 2020-10-15
HRP20191396T1 (hr) 2019-11-01
HUE054745T2 (hu) 2021-09-28
CN107889488A (zh) 2018-04-06
RS59139B1 (sr) 2019-09-30
LT3277681T (lt) 2019-08-12
IL254714A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
ZA201707423B (en) Imidazolonyl quinolines and use thereof as atm kinase inhibitors
IL279258B (en) tyrosine kinase inhibitors
IL277239B (en) mdm2 inhibitors and combinations thereof
SI3380479T1 (sl) Triazolni inhibitorji ACC in uporabe le-teh
EP3171874A4 (en) Imidazolyl kinase inhibitors and uses thereof
PL3380480T3 (pl) Pirazolowe inhibitory acc i ich zastosowania
GB201605126D0 (en) Inhibitors and their uses
IL259150B (en) Pyrimidine derivative and use thereof
SG10201913927VA (en) Kinase inhibitors and uses thereof
IL262400A (en) Erbb inhibitors and uses thereof
HK1250926A1 (zh) 抑制劑及其應用
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses